Lv2
110 积分 2023-09-06 加入
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
29天前
已完结
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
29天前
已完结
Preclinical discovery and clinical development of encorafenib for the treatment of melanoma
30天前
已完结
ERK1/2-targeted Cancer therapies: Recent advances, potential drug resistance, and applicability analysis of emerging technologies
1个月前
已完结
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
3个月前
已完结
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study
5个月前
已完结
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
5个月前
已完结
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
5个月前
已完结
Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study
7个月前
已完结
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
7个月前
已完结
皖公网安备34019202002308
